These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
382 related items for PubMed ID: 10773226
1. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target. Spinale FG, Coker ML, Bond BR, Zellner JL. Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226 [Abstract] [Full Text] [Related]
2. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ. Circulation; 2000 Oct 17; 102(16):1944-9. PubMed ID: 11034943 [Abstract] [Full Text] [Related]
3. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG. Circulation; 1998 May 05; 97(17):1708-15. PubMed ID: 9591765 [Abstract] [Full Text] [Related]
5. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L. Circ Res; 1998 Mar 09; 82(4):482-95. PubMed ID: 9506709 [Abstract] [Full Text] [Related]
6. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. Spinale FG, Gunasinghe H, Sprunger PD, Baskin JM, Bradham WC. J Card Fail; 2002 Dec 09; 8(6 Suppl):S332-8. PubMed ID: 12555141 [Abstract] [Full Text] [Related]
7. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Spinale FG. Circ Res; 2002 Mar 22; 90(5):520-30. PubMed ID: 11909815 [Abstract] [Full Text] [Related]
8. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, Rosenblum W, Kormos RL, Feldman AM. Circulation; 2001 Sep 04; 104(10):1147-52. PubMed ID: 11535571 [Abstract] [Full Text] [Related]
12. Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodelling. Wei Y, Cui C, Lainscak M, Zhang X, Li J, Huang J, Zhang H, Zheng Z, Hu S. J Cell Mol Med; 2011 Apr 04; 15(4):773-82. PubMed ID: 20219015 [Abstract] [Full Text] [Related]
15. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M, Strauer BE. Eur J Heart Fail; 2002 Aug 04; 4(4):439-4. PubMed ID: 12167381 [Abstract] [Full Text] [Related]
17. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Li YY, McTiernan CF, Feldman AM. Cardiovasc Res; 2000 May 04; 46(2):214-24. PubMed ID: 10773225 [Abstract] [Full Text] [Related]
18. Myocardial extracellular matrix remodeling in ischemic heart failure. Gallagher GL, Jackson CJ, Hunyor SN. Front Biosci; 2007 Jan 01; 12():1410-9. PubMed ID: 17127391 [Abstract] [Full Text] [Related]